Betibeglogene autotemcel (beti-cel; brand name Zynteglo outside U.S.; formerly Lentiviral Autologous Beta-Globin Gene Therapy, LentiGlobin) aims to reduce or eliminate the need for regular blood transfusions in patients with transfusion-dependent beta thalassemia by replacing the faulty HBB gene in the patient’s DNA with a healthier copy of the gene.

If you have a Hayes login, click here to view the full report on the Knowledge Center.